Nitrogen Containing Reactant Patents (Class 530/409)
-
Publication number: 20130041134Abstract: The present invention relates generally to methods for preparing polyethylene glycol maleimide (“PEG-Mal”). More specifically, the present invention relates to methods for synthesizing desired molecular weight PEG-Mal by direct ethoxylation of N-(2-hydroxyethyl)maleimide under specific reaction conditions.Type: ApplicationFiled: November 2, 2010Publication date: February 14, 2013Applicant: SANGART ,INC.Inventors: John R. Handley, Jonathon B. McKannan
-
Publication number: 20130039972Abstract: The present invention concerns compositions comprising and methods of identification and use of targeting peptides for placenta or adipose tissue. In certain embodiments, the targeting peptides comprise part or all of SEQ ID NO:5-11, SEQ ID NO:13-22 or SEQ ID NO:144. The peptides may be attached to various therapeutic agents for targeted delivery. Adipose-targeting peptides may be used in methods for weight control, inducing weight loss and treating lipodystrophy syndrome. Adipose-targeting may also be accomplished using other binding moieties selectively targeted to adipose receptors, such as a prohibitin receptor protein complex. Placenta-targeting peptides may be used to interfere with pregnancy, induce labor and/or for targeted delivery of therapeutic agents to placenta and/or fetus. In other embodiments, receptors identified by binding to placenta-targeting peptides may be used to screen compounds for potential teratogenicity.Type: ApplicationFiled: July 26, 2012Publication date: February 14, 2013Inventors: Renata Pasqualini, Wadih Arap, Mikhail G. Kolonin
-
Patent number: 8372960Abstract: It is an objective of the present invention to provide tRNA that has CUA or CCCG as an anticodon and is aminoacylated with an unnatural amino acid, such tRNA being capable of efficiently introducing an unnatural amino acid into a protein without competing with a termination factor. Such tRNA is a mutant tRNA for tryptophan which has G at the 5? end, C as a base pairing with the G at the 5? end, and A as a base next to the C on the 3? side, such tRNA being a mutant tRNA which pairs with a stop codon and has CUA as an anticodon or a mutant tRNA which pairs with a stop codon or a 4-base codon has CUA or CCCG as an anticodon, into which a single base has been inserted just before the CCA sequence at the 3? end.Type: GrantFiled: November 14, 2006Date of Patent: February 12, 2013Assignee: Japan Science and Technology AgencyInventor: Takahiro Hohsaka
-
Publication number: 20130029358Abstract: Immunostimulatory NY-ESO-1 epitopes recognized by MHC-DRB3*0202 (DR52b) or DRB1*0101 (DR1) restricted T cells are described. Methods for their use in diagnostic and therapeutic approaches are also provided. Further, methods for the generation and isolation of MHC class II molecules, either “empty” or peptide-loaded, are provided. Methods for the assembly of MHC class II multimers, for example, tetramers, are also provided. Methods for the detection of T cells binding to specific peptide-loaded MHC class II molecules are also described herein.Type: ApplicationFiled: October 1, 2010Publication date: January 31, 2013Applicant: LUDWIG INSTITUTE FOR CANCER RESEARCH LTD.Inventors: Danila Valmori, Maha Ayyoub, Immanuel F. Luescher, Danijel Dojcinovic
-
Publication number: 20130023648Abstract: A method of forming a cross-linked protein structures includes preparing a solution of protein dissolved in a benign solvent and forming an intermediate protein structure from the solution. The intermediate protein structure can be cross-linked by providing for a specific ratio of chemical cross-linking agents to form the cross-linked protein structure. The solution can be prepared by adding a cross-linker of N-hydroxysuccinimide (NHS) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC) at a ratio of two-to-one of NHS to EDC to alcohol. PBS buffer (20X) can be added to the solution until the volume ratio of PBS buffer (20X) to alcohol is about one-to-one. About 16 percent by weight of protein can be dissolved in the solution. The solution can be electrospun to form an intermediate protein structure. After a period of time, the protein structure can be cross-linked to form the cross-linked protein structure.Type: ApplicationFiled: March 26, 2012Publication date: January 24, 2013Inventors: Gary Wnek, Linghui Meng
-
Publication number: 20130025006Abstract: The present invention includes modified, insecticidal B.t. Cry1Ca proteins, including the proteins designated herein as DIG-109 and DIG-152, as well as variants of DIG-109 and DIG-152, nucleic acids encoding these proteins, methods of controlling pests using the proteins, methods of producing the proteins in transgenic host cells, and transgenic plants that produce the proteins. The DIG-109 and DIG-152 proteins comprise chimeric peptides composed of a core toxin segment of B.t. Cry1Ca and a Cry1Ab protoxin segment. Insecticidally active variants of the DIG-109 and DIG-152 proteins are also described.Type: ApplicationFiled: December 16, 2010Publication date: January 24, 2013Applicant: DOW AGROSCIENCES LLCInventors: Thomas Meade, Stephanie L. Burton, Kenneth Narva, Aaron T. Woosley, Timothy D. Hey, Ignacio M. Larrinua
-
Publication number: 20130018172Abstract: Compositions comprising certain tripeptides which are capable of binding a metal in a square planar orientation, a square pyramidal orientation, or both, are disclosed in processes for modulating tagged peptides or proteins. Such compositions and processes may be used for site-specific chiral inversion of amino acids, site-specific peptide cleavage, and protein purification, among other uses.Type: ApplicationFiled: January 13, 2012Publication date: January 17, 2013Applicants: Echogen, Inc., University of KansasInventors: Jennifer Ann Stowell Laurence, Mary Elizabeth Krause, Timothy A. Jackson, George Laurence
-
Publication number: 20130017169Abstract: Multimeric protein structures are disclosed herein, as well a process for preparing same, and methods employing same for treating various diseases or disorders. The multimeric protein structures comprise at least two monomers of a therapeutic protein, including a TNF-alpha, a luteinizing hormone, an immunoglobin, a TNF-alpha receptor, a CTLA-4, a urate oxidase, a VEGF, a PDGF, a VEGF receptor, a PDGF receptor, an interleukin-17, and/or fragments thereof, the monomers being covalently linked to one another via a linking moiety. The multimeric protein structures exhibit improved performance as compared to the corresponding native proteins, including a longer lasting activity in vivo.Type: ApplicationFiled: March 2, 2011Publication date: January 17, 2013Applicant: PROTALIX LTD.Inventors: Ilya Ruderfer, Orit Shilovittzky, Avidor Shulman, Joseph Shaaltiel, Tehila Ben-Moshe, Talia Shekhter, Yaniv Azulay
-
Publication number: 20130012690Abstract: The present invention provides a method for producing modified stable polypeptides introducing at least one non-natural amino acid into the hydrophobic region of the polypeptide. The thermal and chemical stability of such polypeptides is improved compared to those properties of its corresponding wild type proteins. The invention further provides purified leucine zipper and coiled-coil proteins in which the leucine residues have been replaced with 5,5,5-trifluoroleucines, and the modified proteins so produced demonstrate increased thermal and chemical stability compared to their corresponding wild-type natural proteins.Type: ApplicationFiled: January 20, 2012Publication date: January 10, 2013Applicant: CALIFORNIA INSTITUTE OF TECHNOLOGYInventors: David A. Tirrell, Yi Tang
-
Publication number: 20130011432Abstract: The invention is directed to an adenovirus-antigen conjugate comprising (a) a disrupted adenovirus with a coat protein and (b) an antigen conjugated to the coat protein of the disrupted adenovirus, as well as a conjugate comprising (a) a disrupted adenovirus with a coat protein and (b) an antigen conjugated to the coat protein of the disrupted adenovirus. The invention also provides a method of inducing an immune response against an antigen in a human using the aforementioned conjugates. The invention further provides an adeno-associated viral vector comprising a nucleic acid sequence which encodes an antibody directed against cocaine.Type: ApplicationFiled: March 17, 2011Publication date: January 10, 2013Applicant: CORNELL UNIVERSITY (CCTEC)Inventors: Ronald G. Crystal, Bishnu De, Martin Hicks, Jonathan Rosenberg, Stephen M. Kaminsky
-
Publication number: 20130011338Abstract: The present invention discloses methods and materials for delivering a cargo compound into a cancer cell. Delivery of the cargo compound is accomplished by the use of protein transduction domains derived from cupredoxins. The invention further discloses methods for treating cancer and diagnosing cancer.Type: ApplicationFiled: June 25, 2012Publication date: January 10, 2013Applicant: The Board of Trustees of the University of IllinoisInventors: Ananda Chakrabarty, Tapas Das Gupta, Tohru Yamada, Arsenio Fialho
-
Publication number: 20130011900Abstract: The invention relates to materials and methods of conjugating a water soluble polymer to an oxidized carbohydrate moiety of a therapeutic protein comprising contacting the oxidized carbohydrate moiety with an activated water soluble polymer under conditions that allow conjugation. More specifically, the present invention relates to the aforementioned materials and methods wherein the water soluble polymer contains an active aminooxy group and wherein an oxime or hydrazone linkage is formed between the oxidized carbohydrate moiety and the active aminooxy group on the water soluble polymer, and wherein the conjugation is carried out in the presence of a nucleophilic catalyst.Type: ApplicationFiled: June 4, 2012Publication date: January 10, 2013Applicants: BAXTER HEALTHCARE S.A., BAXTER INTERNATIONAL INC.Inventors: Juergen Siekmann, Stefan Haider, Hanspeter Rottensteiner, Peter Turecek
-
Publication number: 20130004524Abstract: The present invention relates to modified therapeutic proteins, such as e.g. coagula-tion factors. In particular, the present invention relates to conjugated Factor VIII molecules such as e.g. FVII, FVIII, or FIX comprising a hydrophobic side group.Type: ApplicationFiled: February 9, 2011Publication date: January 3, 2013Applicant: Novo Nordisk A/SInventors: Jens Buchardt, Carsten Behrens
-
Publication number: 20130004532Abstract: The present application discloses an improved method for conducting saccharide—protein conjugation reactions using carbodiimide condensation chemistry. Depending on the nature of the saccharide or protein carrier involved, the quality of the conjugate may be improved by adding one of the reaction components slowly to the reaction mixture. Immunogenic compositions are further provided comprising the saccharide-protein conjugates made by the methods disclosed.Type: ApplicationFiled: April 27, 2012Publication date: January 3, 2013Inventors: Ralph Leon BIERMANS, Pierre DUVIVIER
-
Publication number: 20120329998Abstract: Provided is luminescent gold nanomaterial functionalized by N-(4-aminobutyl)-N-ethylisoluminol, methods of preparation and application thereof. The functionalized gold nanoparticle nanomaterial are formed by N-(4-aminobutyl)-N-ethylisoluminol bonding to the surface of the gold nanomaterial. The functionalized gold nanomaterial are prepared by directly reducing chloroauric acid with N-(4-aminobutyl)-N-ethylisoluminol, wherein N-(4-aminobutyl)-N-ethylisoluminol acts as reducer and stabilizer simultaneously. The preparation method is simple, fast and no need of special conditions. The preparation methods can be performed in a wide temperature range, for example, 15-35° C. The size and pattern of the functionalized gold nanomaterial can be specified by choosing the ratio of chloroauric acid to N-(4-aminobutyl)-N-ethylisoluminol. The obtained functionalized nano gold particles exhibit excellent chemiluminescence properties.Type: ApplicationFiled: July 8, 2010Publication date: December 27, 2012Inventors: Hua Cui, Dayong Tian
-
Publication number: 20120329068Abstract: The present invention provides methods, compositions, and kits useful in preparing labeled molecules, which are useful in the detection of binding partners.Type: ApplicationFiled: March 16, 2012Publication date: December 27, 2012Applicant: Biotium, Inc.Inventors: Fei Mao, Wai-Yee Leung, Ching-Ying Cheung, Hye Eun Hoover
-
Publication number: 20120328646Abstract: An immunogenic composition containing a glycan conjugate including a carrier protein, and a glycan including Globo H, an immunogenic fragment thereof, or stage-specific embryonic antigen-4 (SSEA-4), wherein the glycan is conjugated with the carrier protein through a linker.Type: ApplicationFiled: August 7, 2012Publication date: December 27, 2012Applicant: Academia SinicaInventors: Chi-Huey Wong, Chung-Yi Wu, Alice L. Yu, John Yu
-
Publication number: 20120329129Abstract: A magnetic nanoparticle is provided in the disclosure. The magnetic nanoparticle includes a magnetic nanoparticle; a biocompatible polymer of the following formula (II) covalently coupled to the magnetic nanoparticle, wherein R1 is alkyl, aryl, carboxyl, or amino; n is an integer from 5 to 1000; and m is an integer from 1 to 10.Type: ApplicationFiled: August 30, 2012Publication date: December 27, 2012Applicant: INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTEInventors: Wen-Hsiang Chang, Wen-Uan Hsieh, Shiu-Hua Huang, Chin-I Lin, Shian-Jy Jassy Wang, Kelly Teng
-
Publication number: 20120329127Abstract: The present disclosure relates to materials and methods of conjugating a water soluble polymer to a therapeutic protein.Type: ApplicationFiled: May 25, 2012Publication date: December 27, 2012Applicants: BAXTER HEALTHCARE S.A., BAXTER INTERNATIONAL INC.Inventors: Juergen Siekmann, Alfred Weber, Hanspeter Rottensteiner, Peter Turecek
-
Publication number: 20120329176Abstract: Indirectly labelled assay conjugates prepared by a method that includes the step of submitting the binding member comprised by the conjugate to denaturing conditions prior to labelling the binding member. The indirectly labelled assay conjugates demonstrate an increased sensitivity when employed in diagnostic assays compared to assay conjugates prepared by methods that do not include a step of submitting the binding member to denaturing conditions prior to labelling. Processes for the preparation of the indirectly labelled assay conjugates, methods of detecting an analyte comprising the use of the indirectly labelled assay conjugate and kits comprising the indirectly labelled conjugates are also provided.Type: ApplicationFiled: August 31, 2012Publication date: December 27, 2012Applicant: ABBOTT LABORATORIESInventors: Anthony S. Muerhoff, Suresh M. Desai, Thomas P. Leary, George J. Dawson, Robin A. Gutierrez
-
Publication number: 20120322974Abstract: 1,3-Dipole-functional compounds (e.g., azide functional compounds) can be reacted with certain alkynes in a cyclization reaction to form heterocyclic compounds. Useful alkynes (e.g., strained, cyclic alkynes) and methods of making such alkynes are also disclosed. The reaction of 1,3-dipole-functional compounds with alkynes can be used for a wide variety of applications including the immobilization of biomolecules on a substrate.Type: ApplicationFiled: March 13, 2012Publication date: December 20, 2012Applicant: University of Georgia Research Foundation, Inc.Inventors: GEERT-JAN BOONS, Jun Guo, Xinghai Ning, Margaretha Wolfert
-
Publication number: 20120315686Abstract: Disclosed herein are non-natural amino acids and polypeptides that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides. The non-natural amino acids, by themselves or as a part of a polypeptide, can include a wide range of possible functionalities, but typical have at least one aromatic amine group. Also disclosed herein are non-natural amino acid polypeptides that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such polypeptides. Typically, the modified non-natural amino acid polypeptides include at least one alkylated amine group. Further disclosed are methods for using such non-natural amino acid polypeptides and modified non-natural amino acid polypeptides, including therapeutic, diagnostic, and other biotechnology uses.Type: ApplicationFiled: May 9, 2012Publication date: December 13, 2012Applicant: Ambrx, Inc.Inventors: Zhenwei MIAO, Junjie Liu, Thea Norman
-
Publication number: 20120296072Abstract: Provided herein are methods and compositions relating to the attachment of water soluble polymers to proteins. Provided are novel methods for N-terminally modifying proteins or analogs thereof, and resultant compositions, including novel N-terminally chemically modified G-CSF compositions and related methods of preparation. Also provided is chemically modified consensus interferon.Type: ApplicationFiled: August 2, 2012Publication date: November 22, 2012Applicant: AMGEN INC.Inventors: Olaf B. Kinstler, Nancy Elise Gabriel, Christine E. Farrar, Randolph B. DePrince
-
Publication number: 20120295287Abstract: This document provides methods and materials related to detecting neurotransmitters and other biologically active small molecules. For example, methods for detecting and measuring hapten levels in a biological sample using antibodies specific for conjugated haptens are provided.Type: ApplicationFiled: November 8, 2010Publication date: November 22, 2012Applicant: Pharmasan Labs, Inc.Inventors: Gottfried H. Kellermann, Han J.G. Huisman
-
Publication number: 20120288871Abstract: Chemically reactive carbocyanine dyes incorporating an indolium ring moiety that is substituted at the 3-position by a reactive group or by a conjugated substance, and their uses, are described. Conjugation through this position results in spectral properties that are uniformly superior to those of conjugates of spectrally similar dyes wherein attachment is at a different position. The invention includes derivative compounds having one or more benzo nitrogens.Type: ApplicationFiled: July 24, 2012Publication date: November 15, 2012Applicant: LIFE TECHNOLOGIES CORPORATIONInventors: Wai-Yee Leung, Ching-Ying Cheung, Stephen Yue
-
Publication number: 20120289682Abstract: A new and versatile class of cyclic diazodicarboxamides that reacts efficiently and selectively with phenols and the phenolic side chain of tyrosine through an Ene-like reaction is reported. This mild aqueous tyrosine ligation reaction works over a broad pH range and expands the repertoire of aqueous chemistries available for small molecule, peptide, and protein modification. The tyrosine ligation reactions are shown to be compatible with the labeling of native enzymes and antibodies in buffered aqueous solution. This reaction provides a novel synthetic approach to bispecific antibodies. This reaction will find broad utility in peptide and protein chemistry and in the chemistry of phenol-containing compounds.Type: ApplicationFiled: December 23, 2010Publication date: November 15, 2012Inventors: Carlos F. Barbas, III, Hitoshi Ban, Julia Gavrilyuk
-
Publication number: 20120283316Abstract: Disclosed are drug delivery compositions comprising an oligonucleotide-modified nanoparticle and a therapeutic agent. Specifically, disclosed are compositions comprising a number of oligonucleotide molecules in a ratio to therapeutic agent molecules to allow a sufficient transportation of the therapeutic agent molecules into a cell. The therapeutic agents include both hydrophobic and hydrophilic. Different attachments of therapeutic agents in a composition are also described.Type: ApplicationFiled: September 1, 2010Publication date: November 8, 2012Applicant: Northwestern UniversityInventors: Chad A. Mirkin, David A. Giljohann, Weston L. Daniel
-
Publication number: 20120282626Abstract: This invention provides methods and compositions for incorporation of an unnatural amino acid into a peptide using an orthogonal aminoacyl tRNA synthetase/tRNA pair. In particular, an orthogonal pair is provided to incorporate 5-hydroxy-L-tryptophan in a position encoded by an opal mutation.Type: ApplicationFiled: July 11, 2012Publication date: November 8, 2012Applicant: The Scripps Research InstituteInventors: Zhiwen Zhang, Lital Alfonta, Peter Schultz
-
Patent number: 8303922Abstract: A new method is disclosed for the exfoliation of hexagonal boron nitride into mono- and few-layered nanosheets (or nanoplatelets, nanomesh, nanoribbons). The method does not necessarily require high temperature or vacuum, but uses commercially available h-BN powders (or those derived from these materials, bulk crystals) and only requires wet chemical processing. The method is facile, cost efficient, and scalable. The resultant exfoliated h-BN is dispersible in an organic solvent or water thus amenable for solution processing for unique microelectronic or composite applications.Type: GrantFiled: August 24, 2009Date of Patent: November 6, 2012Assignee: The United States of America as represeted by the Administrator of the National Aeronautics and Space AdministrationInventors: Yi Lin, John W. Connell
-
Publication number: 20120276548Abstract: The technology relates in part to multimer conjugates comprising a scaffold linked to two or more polypeptides that specifically interact with a nucleic acid containing beta-D-glucosyl-hydroxymethylcytosine or beta-D-glucosyl-hydroxymethyluracil. The scaffold can be chosen from an antibody, an antibody fragment, a multimerized binding partner that interacts with a binding partner counterpart in each of the polypeptides, a polymer, and a polyfunctional molecule. The polypeptides can be from a kinetoplastid flagellate organism and may comprise a full-length native or modified protein or a fragment thereof that specifically interacts with the beta-D-glucosyl-hydroxymethylcytosine and/or the beta-D-glucosyl-hydroxymethyluracil in the nucleic acid. The conjugates provided herein can be used to detect the presence, absence or amount of beta-D-glucosyl-hydroxymethylcytosine and/or beta-D-glucosyl-hydroxymethyluracil-containing nucleic acid in a sample.Type: ApplicationFiled: April 25, 2012Publication date: November 1, 2012Applicant: SEQUENOM, INC.Inventor: Karsten Schmidt
-
Publication number: 20120277158Abstract: The present invention is directed to conjugates that include a polypeptide capable of crossing the blood-brain barrier or entering one or more cell types attached to a transport vector, i.e., a composition capable of transporting an agent (e.g., a therapeutic agent). In certain cases, the polypeptides are directly conjugated to a lipid or polymeric vector to allow targeted application of a therapeutic agent to treat, for example, a cancer, a neurodegenerative disease, or a lysosomal storage disorder.Type: ApplicationFiled: October 5, 2010Publication date: November 1, 2012Applicant: Angiochem Inc.Inventors: Jean-Paul Castaigne, Michel Demeule, Christian Che, Anthony Regina
-
Patent number: 8299222Abstract: The invention generally relates to hapten compounds comprising either (+) methamphetamine or (+) amphetamine conjugated to a linker. Generally speaking, hapten compounds of the invention may be used to elicit an immune response to one or more of (+) methamphetamine, (+) amphetamine, or (+) MDMA.Type: GrantFiled: November 3, 2009Date of Patent: October 30, 2012Assignee: The Board of Trustees of the University of ArkansasInventors: Samuel M. Owens, Frank Ivy Carroll, Philip Abraham
-
Publication number: 20120269841Abstract: In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. Each mutant toxin includes a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may further include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to antibodies or binding fragments thereof that binds to said immunogenic compositions. In further aspects, the invention relates to isolated nucleotide sequences that encode any of the foregoing, and methods of use of any of the foregoing compositions.Type: ApplicationFiled: April 20, 2012Publication date: October 25, 2012Applicant: WYETH LLCInventors: Maninder K. Sidhu, Annaliesa Sybil Anderson, Robert G. K. Donald, Kathrin Ute Jansen, Narender K. Kalyan, Terri L. Mininni, Justin Keith Moran, Mark E. Ruppen, Michael James Flint
-
Patent number: 8293904Abstract: The present invention provides novel osmium-based electrochemical species for the detection of wide variety of analytes using immunological techniques. The present invention also provides diagnostic kits and test sensors supporting electrode structures that can be used with the osmium-based electrochemical species. The test sensor can be fabricated to support interdigitated arrays of electrodes that have been designed to provide amplification of the electrical signal amplification desired to analyze analytes that may be present at low concentrations.Type: GrantFiled: September 20, 2011Date of Patent: October 23, 2012Assignee: Roche Diagnostics Operations, Inc.Inventors: Eric R. Diebold, Mitali Ghoshal, David Z. Deng, Jane S. C. Tsai
-
Patent number: 8288544Abstract: The present invention provides novel osmium-based electrochemical species for the detection of wide variety of analytes using immunological techniques. The present invention also provides diagnostic kits and test sensors supporting electrode structures that can be used with the osmium-based electrochemical species. The test sensor can be fabricated to support interdigitated arrays of electrodes that have been designed to provide amplification of the electrical signal amplification desired to analyze analytes that may be present at low concentrations.Type: GrantFiled: July 1, 2004Date of Patent: October 16, 2012Assignee: Roche Diagnostics Operations, Inc.Inventors: Eric R. Diebold, Mitali Ghoshal, David Z. Deng, Jane S.C. Tsai
-
Publication number: 20120258077Abstract: The present invention provides novel peptide immunogens comprising influenza virus matrix 2 protein epitopes and related compositions and methods. The present invention relates to a composition comprising a peptide immunogen useful for the prevention and treatment of an influenza virus-mediated disease. The invention also relates to vaccines, immunogenic products and immunogenic compositions containing the peptide immunogens.Type: ApplicationFiled: June 14, 2012Publication date: October 11, 2012Applicant: Theraclone Sciences, Inc.Inventors: Matthew Moyle, Jennifer Mitcham
-
Publication number: 20120259098Abstract: The present invention relates to novel dendrimer compounds and methods of synthesizing the same. In particular, the present invention is directed to novel polyamidoamine (PAMAM) dendrimers, novel dendrimer branching units, methods for synthesizing such novel PAMAM dendrimers and functionalized dendrimers, as well as systems and methods utilizing the dendrimers (e.g., in diagnostic and/or therapeutic settings (e.g., for the delivery of therapeutics, imaging, and/or targeting agents (e.g., in disease diagnosis and/or therapy, etc.))).Type: ApplicationFiled: October 7, 2010Publication date: October 11, 2012Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGANInventors: James R. Baker, JR., Baohua Huang
-
Publication number: 20120258514Abstract: Chemically reactive carbocyanine dyes that are intramolecularly crosslinked between the 1-position and 3?-position, their bioconjugates and their uses are described. 1,3?-crosslinked carbocyanines are superior to those of conjugates of spectrally similar 1,1?-crosslinked or non-crosslinked dyes. The invention includes derivative compounds having one or more benzo nitrogens.Type: ApplicationFiled: January 27, 2012Publication date: October 11, 2012Applicant: AnaSpec IncorporatedInventors: Zhenjun Diwu, Jianheng Zhang, Yi Tang, Xiang Guobing
-
Patent number: 8283319Abstract: The present invention relates to the therapeutic application of the Kazal-type serine protease inhibitor Infestin or domains thereof or modified Kazal-type serine protease inhibitors based on Infestin homologs, which prevent the formation and/or stabilization of three-dimensional arterial or venous thrombi by interfering with proteins involved in activation of the so-called intrinsic coagulation pathway. The present invention also relates to the use of Kazal-type serine protease inhibitors or fragments thereof or modified Kazal-type serine protease inhibitors in the treatment or prophylaxis of a condition or disorder related to arterial thrombus formation, i.e. stroke or myocardial infarction, inflammation, complement activation, fibrinolysis, angiogenesis and/or diseases linked to pathological kinin formation such as hypotonic shock, edema including hereditary angioedema, bacterial infections, arthritis, pancreatitis, or articular gout, Disseminated Intravasal Coagulation (DIC) and sepsis.Type: GrantFiled: February 11, 2008Date of Patent: October 9, 2012Assignee: CSL Behring GmbHInventors: Stefan Schulte, Ulrich Kronthaler, Stefan Schmidbauer, Thomas Weimer, Kay Hofmann
-
Publication number: 20120253022Abstract: The invention is directed to a method of removing a deleterious substance bound to a protein in blood of a patient by introducing a displacer substance into the blood under conditions in which the displacer substance replaces deleterious substance bound to the protein, thereby resulting in additional unbound deleterious substance in the blood, and removing unbound deleterious substance from the blood by extracorporeal renal replacement treatment.Type: ApplicationFiled: June 12, 2012Publication date: October 4, 2012Applicant: Fresenius Medical Care Holdings, Inc.Inventors: Peter Kotanko, Nathan W. Levin
-
Publication number: 20120252691Abstract: Modified nucleotides, and methods to modify nucleotides with a moiety or label, such as biotin, that permits their detection and results in a modified nucleotide, and methods of use of the modified nucleotide in quantitative and qualitative assays.Type: ApplicationFiled: May 29, 2012Publication date: October 4, 2012Applicant: Pierce Biotechnology, Inc.Inventors: Christopher L. Etienne, Kay K. Opperman, Barbara J. Kaboord, Scott Meier, Jean-Samuel Schultz
-
Publication number: 20120244596Abstract: The invention relates to the production of novel proteins exhibiting bonding activity for certain ligands, the so-called anticalins. To this end, the structure of peptides of the lipocalin family is modified by amino acid replacement in their natural ligand binding pocket using generic engineering methods. Alike immunoglobulin, the anticalin thus obtained can be used to identify or bond molecular structures.Type: ApplicationFiled: March 19, 2012Publication date: September 27, 2012Inventors: Arne Skerra, Gerald Beste, Frank Schmidt, Thomas Stibora
-
Publication number: 20120244123Abstract: A purified anti-cancer peptide consisting of amino acids 266 to 287 of Genbank Accession No. O68604 (SEQ ID No. 4), and modified and homologous forms of the peptide are described. The modified or and homologous forms of the peptide include more than contiguous amino acids having at least 75% amino acid sequence identity with at least 8 contiguous amino acids of amino acids 266-287 of Genbank Accession No. O68604 (SEQ ID No.4) defining a motif selected from the group consisting of RRRVQQ (SEQ ID No. 5) and RGRAK (SEQ ID No.1). The peptide(s) can be produced by B. linens, a Brevibacterium commonly used in the production of cheese. There is also provided method for prophylaxis or treatment of cancer in a mammal, comprising treating the mammal with an effective amount of the peptide, or a protein the pepsin cleavage of which yields the peptide.Type: ApplicationFiled: July 17, 2009Publication date: September 27, 2012Inventors: Michael Valentine Agrez, Douglas Dorahy
-
Patent number: 8273833Abstract: The present invention is directed to branched reactive water-soluble polymers comprising at least two polymer arms, such as poly(ethylene glycol), attached to a central aliphatic hydrocarbon core molecule through ether linkages. The branched polymers bear at least one functional group for reacting with a biologically active agent to form a biologically active conjugate. The functional group of the branched polymer can be directly attached to the aliphatic hydrocarbon core or via an intervening linkage, such as a heteroatom, -alkylene-, —O-alkylene-O—, -alkylene-O-alkylene-, -aryl-O—, —O-aryl-, (—O-alkylene-)m, or (-alkylene-O—)m linkage, wherein m is 1-10.Type: GrantFiled: December 8, 2010Date of Patent: September 25, 2012Assignee: Nektar TherapeuticsInventors: Michael David Bentley, Xuan Zhao, Xiaoming Shen, William Dudley Battle, III
-
Publication number: 20120238036Abstract: The object of the present invention is to provide a method for increasing an amount of Protein A to be immobilized on the self-assembled monolayer. Immobilizing Protein A to the self-assembled monolayer through the structure represented following formula (II) obviates the object.Type: ApplicationFiled: May 30, 2012Publication date: September 20, 2012Applicant: PANASONIC CORPORATIONInventor: Yukari HATAOKA
-
Publication number: 20120232463Abstract: A method of making a bacteriochlorin is carried out by condensing a pair of compounds of Formula II to produce the bacteriochlorin, wherein R is an acetal or aldehyde group. The condensing may be carried out in an organic solvent, preferably in the presence of an acid. The bacteriochlorins are useful for a variety of purposes such as active agents in photodynamic therapy, luminescent compounds in flow cytometry, solar cells, light harvesting arrays, and molecular memory devices.Type: ApplicationFiled: April 10, 2012Publication date: September 13, 2012Inventors: Han-Je Kim, Jonathan S. Lindsey
-
Publication number: 20120231459Abstract: A novel method is disclosed for simultaneous detection and quantification of two or more nucleic acid targets, without need for amplification. The method depends on spectral-temporal resolution of chemiluminescence emitted from independent hybridization-induced chemiluminescent signal (HICS) probes. The utility of this method has been demonstrated by use of resolvable N-linked acridinium and 2,7-dimethoxyacridinium ester labeled probes in a homogeneous assay for sensitive and simultaneous independent quantification of several bacterial and fungal target sequences. Compositions and kits for practicing the method of the present invention are also disclosed.Type: ApplicationFiled: April 12, 2012Publication date: September 13, 2012Applicant: GEN-PROBE INCORPORATEDInventors: Kenneth A. BROWNE, Ian WEEKS
-
Patent number: 8263754Abstract: The invention provides amphiphiles for manipulating membrane proteins. The amphiphiles can feature carbohydrate-derived hydrophilic groups and branchpoints in the hydrophilic moiety and/or in a lipophilic moiety. Such amphiphiles are useful as detergents for solubilization and stabilization of membrane proteins, including photosynthetic protein superassemblies obtained from bacterial membranes.Type: GrantFiled: April 8, 2009Date of Patent: September 11, 2012Assignees: Wisconsin Alumni Research Foundation, UChicago Argonne, LLCInventors: Samuel Helmer Gellman, Pil Seok Chae, Philip D. Laible, Marc J. Wander
-
Publication number: 20120219972Abstract: The present invention provides an isolated Ehrlichia peptide and therapeutic and diagnostic uses therefor.Type: ApplicationFiled: January 31, 2012Publication date: August 30, 2012Applicant: The Board of Regents of The University of Texas SystemInventors: Sunil Thomas, David H. Walker
-
Publication number: 20120195922Abstract: Methods for preparing complex multivalent immunogenic conjugates that include simultaneously reacting a plurality or immunogenic-distinct polysaccharides with at least one protein to make the complex multivalent immunogenic conjugates. The simultaneous reaction involves reaction of a hydrazide group on one reactant with an aldehyde or cyanate ester group on the other reactant.Type: ApplicationFiled: April 5, 2012Publication date: August 2, 2012Inventor: Che-Hung Robert Lee